Name: Mologen AG - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Mologen AG

Tracking the rise and fall of next-generation checkpoint targets for cancer

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Management tracks: Denali, Convert

Oncologie, Mologen negotiating larger lefitolimod deal

Ministring theory in practice

Oncologie raises $16.5M for dual U.S.-China strategy

Oncologie raises $16.5M for dual U.S.-China strategy

Mologen reports final Phase II data for lefitolimod in extensive-stage SCLC

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

HIV shock and kill combo shows promise in monkeys